Targeting the Resistant Tumor Microenvironment in Lymphoma: From Basic Science to Artificial Intelligence

Dear Colleagues,

Lymphomas are heterogeneous groups of neoplasms that originate from the aberrant proliferation of immune cells, including B lymphocytes, T lymphocytes, and natural killer (NK) cells. While tumoral initiation is associated with the accumulation of genetic mutations, the tumor microenvironment (TME) is a crucial infrastructure in lymphomagenesis, as they are strongly dependent on the TME for various steps of malignancies. The TME constitutes a dynamic ecosystem composed of immune and stromal cells, implicated from progression to metastasis. Despite recent advances in lymphoma treatment, achieving a durable response remains poor, leading to relapse and resistance to various immunotherapies. 

Current challenges in reaching a complete response include the high degree of heterogeneity in the TME composition and the multitude mechanisms through which the TME can counteract the efficacy of therapy. The high pressure exerted by treatments results in the modulation of TME response prompting necessary signals for the development of resistant clones against therapeutic regimens. 

Therefore, further research is necessary to explore the complex molecular and cellular ecosystem of lymphoma disease and reveal innovative microenvironmental targets that can reduce the high incidence of relapse and resistance and minimize the development of drug-resistant clones.  

This Special Issue welcomes reviews and innovative research articles spanning from basic science to artificial intelligence approaches on the TME-lymphoma crosstalk. The aim is to enhance our understanding of the influence of TME on malignancies and improve therapy effectiveness.

Dr. Rada Amin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lymphoma
• tumor microenvironment
• tumor–immune cell interaction
• immunotherapy
• machine learning
• bioimaging
• artificial intelligence
• immunology